The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's Disease (PD) is a common and progressive neurodegenerative disorder
characterised by motor impairments as well as non-motor symptoms. While dopamine …

The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

Abstract Objective The Parkinson's Progression Markers Initiative (PPMI) is an
observational, international study designed to establish biomarker‐defined cohorts and …

Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long
been characterised by the classical motor features of parkinsonism associated with Lewy …

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a
relevant history of Dr. James Parkinson's himself and what he described accurately and …

Parkinson’s Disease and Its Management - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …

Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic
mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa …

The greatest unmet therapeutic need in Parkinson's disease is the development of treatment
that slows the relentless progression of the neurodegenerative process. The concept of …